Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
OncoCyte financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.1
2024-10-29
Market Capitalization
$52.2 M
2024-10-29
Revenue
$4.1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2M | 7.7M | 958.0K | 1.5M | 1.9M | 4.1M | ||||
| Cost of goods sold | 1.9M | 4.2M | 880.0K | 1.0M | 1.1M | 1.8M | ||||
| Gross profit | (639.0K) | 188.0K | (18.0K) | 413.0K | 740.0K | 2.3M | ||||
| Gross profit margin, % | -52.5% | -1.9% | 39.3% | 56.8% | ||||||
| General and administrative expense | 5.5M | 9.2M | 7.0M | 13.3M | 16.8M | 22.3M | 21.9M | 11.2M | 10.2M | |
| Operating expense total | 11.1M | 18.8M | 15.2M | 22.2M | 29.1M | 74.4M | 18.0M | 25.5M | 61.8M | |
| Depreciation and amortization | 7.0K | |||||||||
| EBIT | (11.1M) | (18.8M) | (15.2M) | (22.2M) | (29.7M) | (74.2M) | (18.0M) | (25.1M) | (61.0M) | |
| EBIT margin, % | -2443.3% | -1878.6% | -3245.1% | |||||||
| Investment income | (281.0K) | (1.5M) | (270.0K) | |||||||
| Interest expense | 217.0K | 216.0K | 299.0K | 252.0K | (209.0K) | 77.0K | 52.0K | 84.0K | ||
| Pre tax profit | (31.2M) | (73.4M) | (18.6M) | (24.9M) | (60.7M) | |||||
| Income tax expense | (1.3M) | (9.3M) | ||||||||
| Net Income | (11.2M) | (19.4M) | (15.8M) | (22.4M) | (29.9M) | (64.1M) | (72.9M) | (27.8M) | (60.7M) | |
| EPS | (3.0) | (4.7) | (1.6) |